Nestle pays $2 billion to secure Aimmune’s allergy treatment

[cafead]

via Nestle said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around 25.6%, at $2.6 billion.

article source